High Prevalence of Germline DNA-Repair Defects (DRD) in Advanced Cancer Patients Detected Through Precision Medicine Program

被引:0
|
作者
Sailer, Verena [1 ]
Zhang, Tuo [1 ]
Mosquera, Juan Miguel [1 ]
Pisapia, David J. [1 ]
Pauli, Chantal [1 ]
Robinson, Brian [1 ]
Rao, Rema A. [1 ]
Cyrta, Joanna [1 ]
Kim, Rob [1 ]
McNarty, Terra J. [1 ]
Schiffman, Marc H. [1 ]
Nanus, David M. [1 ]
Tagawa, Scott T. [1 ]
Sboner, Andrea [1 ]
Elemento, Olivier [1 ]
Beltran, Himisha [1 ]
Rubin, Mark A. [1 ]
机构
[1] Weill Cornell Med, New York, NY USA
关键词
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
1857
引用
收藏
页码:462A / 462A
页数:1
相关论文
共 43 条
  • [31] Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)
    Smith, M. R.
    Sandhu, S. K.
    George, D. J.
    Chi, K. N.
    Saad, F.
    Thiery-Vuillemin, A.
    Stahl, O.
    Olmos, D.
    Danila, D.
    Gafanov, R.
    Castro, E.
    Moon, H.
    Joshua, A. M.
    Mason, G. E.
    Espina, B. M.
    Liu, Y.
    Bevans, K. B.
    Lopez-Gitlitz, A.
    Francis, P.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S632 - S633
  • [32] Cyclin-Dependent Kinase 4/6=Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes
    Bruno, Luisina
    Ostinelli, Alexis
    Waisberg, Federico
    Enrico, Diego
    Ponce, Carolina
    Rivero, Sergio
    Blanco, Albano
    Zarba, Martin
    Loza, Martin
    Fabiano, Veronica
    Amat, Mora
    Teresa Pombo, Maria
    Noro, Laura
    ChacOn, Matias
    ColO, Federico
    ChacOn, Reinaldo
    Nadal, Jorge
    Nervo, Adriin
    Costanzo, Victoria
    JCO PRECISION ONCOLOGY, 2022, 6
  • [33] Prostatakarzinom-Biomarkerstudie zur Bestimmung der Häufigkeit von DNA-Reparaturdefekten bei Männern mit metastasiertem Prostatakarzinom – PREVALENCEProstate cancer biomarker study to determine the frequency of DNA-repair defects in men with metastatic prostate cancer—PREVALENCE
    H. Rexer
    H. Belz
    M. Bögemann
    Forum, 2022, 37 (6) : 482 - 483
  • [34] Impact of germline DNA-repair gene BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-naive prostate cancer: A single center analysis.
    Matveev, Vsevolod Borisovich
    Lyubchenko, Liudmila
    Kirichek, Andrey
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects
    Smith, Matthew R.
    Sandhu, Shahneen
    George, Daniel J.
    Chi, Kim Nguyen
    Saad, Fred
    Thiery-Vuillemin, Antoine
    Stahl, Olaf
    Olmos, David
    Danila, Daniel C.
    Gafanov, Rustem
    Castro, Elena
    Moon, Helen
    Joshua, Anthony M.
    Mason, Gary E.
    Espina, Byron M.
    Liu, Yan
    Lopez-Gitlitz, Angela
    Francis, Peter
    Bevans, Katherine B.
    Fizazi, Karim
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (07): : 758 - 768
  • [36] Real-world prevalence of homologous recombination repair gene (BRCA1/2 and ATM) mutations (HRRm) in patients (pts) with advanced prostate cancer (aPC) as detected by comprehensive genomic profiling (CGP) of circulating cell-free DNA (cfDNA)
    Sayegh, Nicolas
    Swami, Umang
    Barata, Pedro C.
    Lilly, Michael B.
    Nussenzveig, Roberto
    Hensel, Chuck
    Bryce, Alan Haruo
    Bilen, Mehmet Asim
    Heath, Elisabeth, I
    Nandagopal, Lakshminarayanan
    Garje, Rohan
    Saylor, Philip James
    Babiker, Hani M.
    Vaena, Daniel A.
    Kohli, Manish
    Pal, Sumanta K.
    Sartor, Oliver A.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [37] Efficacy of neoadjuvant docetaxel plus cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations
    Chi, Chenfei
    Liu, Jiazhou
    Fan, Liancheng
    Zhu, Yinjie
    Wang, Yanqing
    Sha, Jianjun
    Huang, Yiran
    Dong, Baijun
    Pan, Jiahua
    Xue, Wei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [38] Laboratory -Prostate cancer High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-na??ve metastatic prostate cancer ?Results from a prospective pilot study using a 37 gene panel
    Nientiedt, Cathleen
    Endris, Volker
    Jenzer, Maximilian
    Mansour, Josef
    Sedehi, Nassim Tawanaie Pour
    Pecqueux, Carine
    Volckmar, Anna-Lena
    Leichsenring, Jonas
    Neumann, Olaf
    Kirchner, Martina
    Hoveida, Shirin
    Lantwin, Philippa
    Kaltenecker, Katrin
    Dieffenbacher, Svenja
    Gasch, Claudia
    Hofer, Luisa
    Franke, Desiree
    Tosev, Georgi
    Goertz, Magdalena
    Schuetz, Viktoria
    Radtke, Jan-Philipp
    Nyarangi-Dix, Joanne
    Hatiboglu, Gencay
    Simpfendoerfer, Tobias
    Schoenberg, Gita
    Isaac, Sanjay
    Teber, Dogu
    Koerber, Stefan A.
    Christofi, Georgia
    Czink, Elena
    Kreuter, Rebecca
    Apostolidis, Leonidas
    Kratochwil, Clemens
    Giesel, Frederik
    Haberkorn, Uwe
    Debus, Juergen
    Sueltmann, Holger
    Zschaebitz, Stefanie
    Jaeger, Dirk
    Duensing, Anette
    Schirmacher, Peter
    Gruellich, Carsten
    Hohenfellner, Markus
    Stenzinger, Albrecht
    Duensing, Stefan
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (07)
  • [39] Canadian cancer trials group trial IND.231: A phase 1 trial evaluating CX-5461, a novel first-in-class G-quadruplex stabilizer in patients with advanced solid tumors enriched for DNA-repair deficiencies
    Hilton, John
    Gelmon, Karen
    Cescon, David
    Tinker, Anna
    Jonker, Derek
    Goodwin, Rachel
    Laurie, Scott
    Hansen, Aaron
    Aparicio, Samuel
    Soong, John
    Hagerman, Linda
    Lui, Hongbo
    Bedard, Philippe
    Pritchard, Kathleen
    Tu, Dongsheng
    Seymour, Lesley
    CANCER RESEARCH, 2020, 80 (04)
  • [40] Phase II trial of pembrolizumab for patients suffering from metastatic castration resistant prostate cancer (mCRPC) with DNA repair defects, high tumour mutation burden, and/or high CD3 counts (PERSEUS1).
    Rescigno, Pasquale
    de la Maza, Maria Dolores Fenor
    Burnett, Stephanie M.
    Villacampa, Guillermo
    Stiles, Morgaine
    Cafferty, Fay Helen
    Beije, Nick
    Carreira, Suzanne
    Figueiredo, Ines
    Flohr, Penelope
    Gurel, Bora
    Bertan, Claudia
    Westaby, Daniel
    Chandran, Khobe
    Crespo, Mateus
    Perna, Carla
    Tunariu, Nina
    Sharp, Adam
    Yap, Christina
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 138 - 138